- Identification of disease genes and/or signalling pathways for use in target selection or drug reprofiling; or - Characterisation of disease genes or signalling pathways to inform risk management strategies, define patient criteria for inclusion in studies and stratified clinical study designs; or - Identification of potential markers of medicine efficacy and/or safety response.

Any intellectual property generated is expected to be retained by the institution, with a return to London Genetics upon its exploitation. The company's founding partners are all academic and medical centres with significant clinical and genetic expertise.

The immunotherapy project will investigate genetic regulation of production of natural killer cells, which are involved in protection against diseases from cancer to malaria. The second team will be involved in identifying and validating gene variants associated with the weight gain that often occurs in patients taking atypical antipsychotics for the treatment of schizophrenia. The cardiovascular project will look at drug target validation by using gene variants as a model of target modification.

Dominique Kleyn, CEO of London Genetics, said, 'We are delighted to be making these proof-of-concept awards which should provide further validation of our business model, and highlight our links with first-class academic teams. The biopharmaceutical industry is realising the potential of pharmacogenetics in helping it meet the myriad of challenges it faces, as we discuss in a recent MedNous commentary.'

SOURCE London Genetics Ltd